A Clinical Trial Using Metronomic Oral Low-dose Cyclophosphamide Alternating With Low-dose Oral Methotrexate With Continuous Celecoxib and Weekly Vinblastine in Children and Adolescents With Relapsed or Progressing soliD Tumours. (SFCE METRO 01)
To establish the anti-tumour effect of this metronomic combination regimen defined by progression-free survival (PFS) after two cycles of treatment (4 months) and 12 months of treatment, as well as response rate after any number of cycles of treatment ("best response").
To define the safety profile of the combination. To characterize pharmacodynamics of the drug combination with the use of angiogenic markers (CEP, CEC, microparticles).
Drug: celecoxib, Vinblastine, Cyclophosphamide , methotrexate ,
|Study Design:||Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||A Phase II Clinical Trial Using Metronomic Oral Low-dose Cyclophosphamide Alternating With Low-dose Oral Methotrexate With Continuous Celecoxib and Weekly Vinblastine in Children and Adolescents With Relapsed or Progressing Solid Tumours.|
- Anti-tumour efficacy [ Time Frame: 3 YEARS ]
- Safety AND Pharmacodynamic Study [ Time Frame: 3 YEARS ]
|Study Start Date:||November 2010|
|Estimated Study Completion Date:||March 2016|
|Estimated Primary Completion Date:||November 2015 (Final data collection date for primary outcome measure)|
|Experimental: traetment||Drug: celecoxib, Vinblastine, Cyclophosphamide , methotrexate ,|
Multi-center, combination phase II study, open-label, non-comparative, non-randomized.
All progressive or recurrent solid tumours will be included in the Phase II study, provided there are no curative options anymore.
Total expected number of patients (minimum maximum): 54 to 90 (2-stage design)
Please refer to this study by its ClinicalTrials.gov identifier: NCT01285817
|Contact: ARNAUD VERSCHUUR||04 91 38 84 firstname.lastname@example.org|
|Assistance Publique Hopitaux de Marseille||Recruiting|
|Marseille, France, 13354|
|Contact: arnaud verschuur email@example.com|
|Study Director:||BERNARD BELAIGUES||Assistance Publique hôpitaux de Marseille|